Results 201 to 210 of about 19,810 (255)

The South Australian ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival. [PDF]

ESMO Gastrointest Oncol
Altus LM, Forster JC, Mercurio J, Kitchener M, Corsini N, Nenke M, Price T, Patel D, Chew R, Moffat D, Unger S, Cehic G.   +11 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival. [PDF]

Cancers (Basel)
Perrone E, Calcagni ML, Leccisotti L, Moretti R, Ghai K, Eismant A, Parkar T, Greifenstein L, Baum RP.   +8 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: how important is internal dosimetry?

, 2019
Christoph Trauernicht, P. D. du Toit
openalex   +1 more source

Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up. [PDF]

J Nucl Med
Severi S, Grassi I, Bongiovanni A, Nicolini S, Marini I, Arpa D, Ranallo N, Azzali I, Di Iorio V, Sarnelli A, Manuela M, Amadori E, Fabbri L, Bartolini D, Tosatto L, Di Meco F, Gurrieri L, Riva N, Calabro L, Matteucci F, Paganelli G, Sansovini M.   +21 more
europepmc   +1 more source

Outcome of ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Progressive Metastatic Neuroendocrine Tumors from a Tertiary Care Center. [PDF]

Indian J Endocrinol Metab
Mathew D, Sunny SS, Benjamin J, John JR, Jebasingh FK, Georgy JT, Singh A, Oommen R.   +7 more
europepmc   +1 more source

Efficacy and Safety of Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis of Comparative Studies.

Cureus
Zhao J, Pei X, Li Y.
europepmc   +1 more source

Investigating the Radiobiological Response to Peptide Receptor Radionuclide Therapy Using Patient-Derived Meningioma Spheroids. [PDF]

Cancers (Basel)
Reuvers TGA, Grandia V, Brandt RMC, Arab M, Maas SLN, Bos EM, Nonnekens J.   +6 more
europepmc   +1 more source

Aspects of receptor scintigraphy with neuropeptides [PDF]

, 1995
Breeman, W.A.P. (Wouter)
core  

Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors. [PDF]

Cancers (Basel)
Alayli A, Ngo H, Sikaria D, Ahmed A, Salloum E, Strosberg JR, Al-Toubah TE, Kis B, Haider M, El-Haddad G.   +9 more
europepmc   +1 more source

Clinical characteristics and treatment patterns of patients with gastroenteropancreatic neuroendocrine neoplasia in Germany receiving peptide receptor radionuclide therapy: A real-world data registry-based study. [PDF]

Medicine (Baltimore)
von Hessert-Vaudoncourt C, Maasberg S, Begum N, Rinke A, Pöppel T, Sipos B, Grohe C, Fottner C, Stintzing S, Grabowski P, German NET Registry.   +10 more
europepmc   +1 more source